Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Xilio Therapeutics (XLO) FCF Margin (2024 - 2025)

Xilio Therapeutics' FCF Margin history spans 2 years, with the latest figure at 91.76% for Q3 2025.

  • For Q3 2025, FCF Margin rose 51332.0% year-over-year to 91.76%; the TTM value through Sep 2025 reached 55.28%, changed N/A, while the annual FY2024 figure was 290.26%, N/A changed from the prior year.
  • FCF Margin for Q3 2025 was 91.76% at Xilio Therapeutics, up from 180.7% in the prior quarter.
  • Across five years, FCF Margin topped out at 979.04% in Q1 2025 and bottomed at 821.52% in Q4 2024.